A Follow-Up Study to Monitor Therapeutic Response in Light Chain Cardiac Amyloidosis Using Beta-amyloid PET/CT
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This was a single center, prospective cohort study that is evaluating the ability of beta-amyloid dynamic PET/CT to detect potential therapeutic changes in subjects under treatment for AL-CA after one year had elapsed since their baseline beta-amyloid PET/CT. Demographic, clinical and PET imaging data were collected to characterize potential changes since their baseline scans.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 y;
• were proven newly diagnosed AL-CA by standard criteria;
• subsequently received first-line therapies including anti-plasma cell therapy or targeted therapy;
• must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Li Huo
huoli@pumch.cn
+86 18612672038
Backup
Xuezhu Wang
xuezhu1226@163.com
+86 19801117760
Time Frame
Start Date:2020-06-03
Estimated Completion Date:2027-12-31
Participants
Target number of participants:60
Treatments
Experimental: 11C-PIB PET/CT dynamic imaging
Individuals with light chain systemic amyloidosis with cardiac involvement will undergo baseline 11C-PIB PET/CT dynamic scan (30min) and a follow-up PET/CT dynamic scan at baseline and at 12 months after initiation of plasma cell therapy/targeted therapy, as well as the heavy metal analysis of the blood at baseline, and every 12 month after initiation of therapy.
Individuals with light chain systemic amyloidosis with cardiac involvement will undergo baseline 18F-Florbetapir PET/CT dynamic scan (60min) and a follow-up PET/CT dynamic scan at baseline and at 12 months after initiation of plasma cell therapy/targeted therapy, as well as the heavy metal analysis of the blood at baseline, and every 12 month after initiation of therapy.